PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q3 2026, worth $94.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $99.0M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +1 vs. previous quarter
- 64
- 13F valueReported value at the end of Q3 2026
- $94.4M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$77.7M
- No comparable prior period
- Free cash flow, FY2025
- -$73.6M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.15M
- Shares sold short
- Change
- −131.5K
- −5.8% vs. previous
- Days to cover
- 5.62
- At average daily volume
Superinvestors holding PMVP, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding PMVP at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by PMV Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2025 (view filing)5:19 PM ET | Oct 23 | 4 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −1.00M | $1.52 | −$1.52M | −16.7%4.98M after | |
| Sep 12, 2025 (view filing)5:09 PM ET | Sep 10 | 2 days | OrbiMed Advisors LLC and 1 other10% Owner | SSale | −500.0K | $1.80 | −$900.0K | −7.7%5.98M after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Ticktin RobertGeneral Counsel & COO | SSale | −23.2K | $1.06 | −$24.5K | −19.0%98.7K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Jalota DeepikaChief Development Officer | SSale | −33.1K | $1.06 | −$35.0K | −26.9%90.0K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Carulli MichaelChief Financial Officer | SSale | −28.2K | $1.06 | −$29.9K | −32.0%60.1K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Mack David HenryPresident and CEO | SSale | −58.4K | $1.06 | −$61.9K | −9.8%536.1K after | |
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Jalota DeepikaChief Development Officer | SSale | −7.22K | $1.50 | −$10.8K | −5.8%118.3K after | |
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Carulli MichaelChief Financial Officer | SSale | −2.89K | $1.50 | −$4.34K | −3.2%88.4K after | |
| Nov 24, 2023 (view filing)4:38 PM ET | Nov 22 | 2 days | OrbiMed Advisors LLC and 2 others10% Owner | SSale | −87.8K | $2.23 | −$195.8K | −100.0%0 after | |
| Sep 18, 2023 (view filing) | Sep 15 | 3 days | Jalota DeepikaChief Development Officer | SSale | −4.10K | $6.62 | −$27.2K | −12.1%29.9K after |
Top 10 13F holders, Q3 2026
See all 64 holdersThe largest institutional positions in PMV Pharmaceuticals, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 7,330,000 | $12.2M | 6.57% | +2,000,000+37.5% | Added |
| Tang Capital Management LLC | 7,285,085 | $12.2M | 0.56% | +3,040,000+71.6% | Added |
| Samsara BioCapital, LLC | 7,240,000 | $12.1M | 1.15% | +7,240,000 | New |
| Sio Capital Management, LLC | 3,634,137 | $6.07M | 1.29% | +1,000,000+38.0% | Added |
| Vanguard Capital Management LLC | 3,083,667 | $5.15M | 0.00% | +1,071,647+53.3% | Added |
| ADAR1 Capital Management, LLC | 2,700,349 | $4.51M | 0.19% | +2,499,341+1,243.4% | Added |
| Euclidean Capital LLC | 2,627,643 | $4.39M | 1.36% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 2,429,330 | $4.06M | 0.00% | +475,194+24.3% | Added |
| Adage Capital Partners GP, L.L.C. | 2,360,000 | $3.94M | 0.01% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 2,285,479 | $3.81M | 0.00% | +69,585+3.1% | Added |
Holders of 5% or more of PMVP
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of PMV Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Tang Capital Management LLC | 13G/A | 9.99%7.57M shares | +1.09 ppfrom 8.90% | Sep 23, 20252 filings | Nov 16, 2026 | SEC |
| Samsara BioCapital, L.P. | 13G | 9.90%7.58M shares | New | Sep 15, 20261 filing | Sep 15, 2026 | SEC |
| BML Investment Partners, L.P. | 13G/A | 9.90%5.29M shares | +3.20 ppfrom 6.70% | Dec 12, 20244 filings | Feb 9, 2026 | SEC |